17ohp Compounded denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for 17ohp compounded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Claim as Duplicate Therapy

Blue Cross Blue Shield's duplicate-therapy edit flags a claim when their system detects that another progesterone-based agent is already active on your profile — most commonly a commercially manufactured progesterone product already being dispensed. The insurer's logic is that two therapies serving the same clinical purpose represent unnecessary overlap, so the newer or less preferred agent is rejected automatically.

This denial is frequently wrong in context. Compounded 17-hydroxyprogesterone caproate occupies a distinct clinical niche: your prescriber has made an individualized medical judgment that the compounded formulation is appropriate for your specific situation, and that judgment may rest on documented tolerability, administration factors, or a history with other agents. That clinical distinction is your appeal leverage.

## Federal Appeal Rights

You have layered federal protections regardless of how your plan is structured:

• ACA §2719 / state external review: If internal appeals fail, you are entitled to an independent external review by an accredited Independent Review Organization (IRO). Request this in writing within the window specified in your denial notice — typically around four months from the denial date, though your plan document controls the exact deadline.
• ERISA §503 (self-funded plans): Requires a full and fair review of every adverse benefit determination, with written reasoning for the denial.
• Expedited review: If your condition makes the standard timeline a threat to health, request expedited internal and external review simultaneously.

## Concrete Appeal Steps

1. Obtain the denial letter and identify the exact duplicate-therapy rule cited. 2. Pull the insurer's published Coverage/Medical Policy for progesterone agents and the duplicate-therapy edit logic. 3. Have your prescriber write a medical-necessity letter explaining why the compounded formulation is clinically distinct — not interchangeable — with any other progesterone product on your profile. 4. Compile the documentation categories below and submit within your plan's internal-appeal deadline (usually 180 days from denial).

## Documentation to Gather

• Diagnosis confirmation: Obstetric records establishing the clinical indication, including gestational history.
• Prior-treatment history: Dates, agents tried, outcomes, and reasons for transitions — demonstrating the treatment path that led to this prescription.
• Clinical severity from the chart: Relevant risk factors documented by your provider.
• Prescriber letter: A statement explaining the medical rationale for the compounded formulation specifically, including why any currently active progesterone product does not serve the same clinical purpose.

## Criteria-Mapping Structure

For the strongest appeal, create a side-by-side table:

| Policy Requirement | Chart Evidence Supporting Your Case | |---|---| | Copy each criterion from BCBS's duplicate-therapy policy | Your prescriber's documented reasoning for this specific formulation | | Any formulary-exception criteria listed in the policy | Corresponding clinical record entries with dates |

Consult the insurer's published medical policy directly — requirements can vary by BCBS affiliate and plan year — and match every stated criterion to a documented chart fact.